Given these findings, tRF-1:28-Val-CAC-2 holds promise as a novel target for efforts to diagnose and/or treat NPC, However, how to apply it to clinical practice is still the focus of research, Whether precise delivery of tumor suppressor tsRNAs or targeting tRF-1:28-Val-CAC-2 expression with drugs will require further investigation and rigorous preclinical testing. The gene discussed is TERF1; the disease is neoplasm.